Kyntra Bio (NASDAQ:KYNB) Downgraded by Wall Street Zen to “Sell”

Wall Street Zen lowered shares of Kyntra Bio (NASDAQ:KYNB) from a hold rating to a sell rating in a research report sent to investors on Saturday morning.

Several other equities analysts also recently weighed in on the company. Weiss Ratings assumed coverage on Kyntra Bio in a research report on Wednesday, January 14th. They set a “sell (d+)” rating on the stock. Zacks Research downgraded Kyntra Bio from a “strong-buy” rating to a “hold” rating in a research report on Friday, February 6th. Finally, HC Wainwright upgraded shares of Kyntra Bio to a “strong-buy” rating in a research report on Friday, February 27th. One research analyst has rated the stock with a Strong Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Hold”.

Kyntra Bio Trading Down 2.3%

Shares of NASDAQ KYNB opened at $7.13 on Friday. The company has a market capitalization of $28.88 million, a P/E ratio of 0.16 and a beta of 0.84. Kyntra Bio has a 52-week low of $4.85 and a 52-week high of $12.60. The business has a 50 day moving average price of $7.74.

About Kyntra Bio

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes.